Pharmaceutical water is the cleanest engineered water in routine industrial production, and the hardest to validate. A textile-mill RO that drifts 20% on permeate quality is an operations problem. A pharma WFI distribution loop that drifts 0.5 µS/cm on conductivity is a deviation, a CAPA, and potentially a batch loss.
Pakistani pharma manufacturers — both local producers under DRAP and contract manufacturers exporting under WHO-PQ, EU-GMP, or US-FDA scope — operate under the same water-quality monographs as their global counterparts. Here's the chemistry and validation logic behind it.
The three pharma water grades
| Grade | USP / Ph.Eur. spec | Typical use | Production route |
|---|---|---|---|
| Purified Water (PW) | Conductivity ≤ 1.3 µS/cm @ 25°C (stage 1), TOC ≤ 500 ppb, no objectionable microorganisms, endotoxins not specified | Granulation, coating, cleaning, ingredient water for non-parenteral solid and liquid dosage forms | Pretreatment → softener → RO single- or double-pass → EDI → distribution at 20–25°C with periodic sanitisation |
| Highly Purified Water (HPW) — Ph.Eur. only | Same as WFI but produced by non-distillation | Equivalence to WFI for non-parenteral uses where Ph.Eur. is acceptable | RO + EDI + UF (typically 6000–10000 Da cutoff) |
| Water for Injection (WFI) | Conductivity ≤ 1.3 µS/cm @ 25°C, TOC ≤ 500 ppb, endotoxin ≤ 0.25 EU/mL, sterile by validation | Parenteral product manufacture, final cleaning of product-contact surfaces, lyophilised reconstitution | Historically distillation only; USP/Ph.Eur. now permit membrane-based (RO + EDI + UF) provided validated equivalence; distribution at > 80°C continuous or with cycled sanitisation |
Pretreatment is where most validation failures start
The RO / EDI / distillation core gets all the attention; the pretreatment is what actually fails. Standard pretreatment for a PW or WFI generator:
- Multimedia or carbon filter — remove particulates and free chlorine (dechlorination protects downstream membranes and resins)
- Softener — protect downstream RO from hardness scaling, especially in Pakistani makeup with intermittent hardness leakage
- 5 µm cartridge — final particulate polish
- UV (254 nm) — pre-RO microbial control if feed is biologically loaded
- Antiscalant injection — UN-307 class at 2–4 ppm into the RO feed; required for any RO at >60% recovery on most Pakistani makeup
Validation failures we see most often: chlorine breakthrough on an exhausted carbon bed (visible on the RO permeate as oxidative membrane damage 90 days later), softener regeneration synchronisation drift (intermittent hardness through to RO), and antiscalant under-dosing on hard makeup (CaCO₃ deposition on the RO reject side, normalised permeate flow decline).
The RO + EDI core
For PW production from Pakistani municipal or tubewell makeup, the workable architecture is double-pass RO followed by EDI (continuous electrodeionisation):
- First-pass RO: 75% recovery, polyamide TFC membranes, antiscalant-protected, removes ~99% of dissolved solids.
- Second-pass RO: 85% recovery, often pH-elevated for silica and TOC rejection, polishes the first-pass permeate.
- EDI module: takes the second-pass RO permeate to <0.1 µS/cm resistivity. EDI is sensitive to free chlorine, hardness, and silica — all of which should be at vanishing levels by this stage.
For WFI by distillation, the chemistry pretreatment is the same; the distillation column or multi-effect still replaces EDI as the final purification step.
Distribution loop chemistry — the place WFI systems fail
Producing WFI clean is straightforward; keeping it clean in a distribution loop is what costs most pharma operators their validation. The loop must be:
- Continuously circulating at ≥ 1 m/s velocity to prevent biofilm formation. Dead legs > 6 pipe diameters are deviations.
- Held at > 80°C continuously (hot WFI loop) or sanitised on a schedule (typically 85°C for 1 hour weekly, with documented temperature distribution).
- Constructed in passivated or electropolished 316L with sanitary tri-clamp connections and orbitally welded permanent joints.
- Monitored continuously for conductivity and TOC; periodically (every batch or every 24 hours per SOP) for endotoxin and bioburden.
Sanitisation chemistry
For PW loops at 20–25°C, periodic sanitisation is required. Options:
- Hot water (80–85°C circulating for 1 hour) — most common, no chemistry residual to remove
- Ozone (0.2–0.5 ppm continuously or shock-dosed at 1–2 ppm) — preferred for cold WFI / cold PW systems; ozone is decomposed by UV at point-of-use
- Peracetic acid or hydrogen peroxide — used for periodic SIP of distribution skids; not for continuous dosing
Chlorine-based sanitisers are not used downstream of RO in pharma loops — even trace residual destroys polyamide membranes if upstream protection fails.
Validation overview
Pharma water validation is a three-phase process:
- Phase 1 (2–4 weeks): intensive sampling, daily testing at every point of use, identifies system stability issues
- Phase 2 (2–4 weeks): continued intensive sampling, verifies that operating procedures hold quality within spec
- Phase 3 (12 months): routine sampling per SOP, demonstrates that the system holds spec across seasonal feed variation
A correctly designed and operated pharma water system passes phase 1 immediately and holds quality through phase 3 with no excursion. A poorly designed one fails phase 1 in week one and the operator spends the next nine months chasing remediation.
For pharma water system design review, validation support, or troubleshooting on existing PW / WFI loops, get in touch. See also UN-307 application on Karachi pharma and UN-611 RO membrane biocide.